VORICONAZOLE MYLAN Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole mylan

mcdermott laboratories ltd t/a gerard laboratories - voriconazole - film coated tablet - 200 milligram - voriconazole

VORICONAZOLE ROWEX 50 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole rowex 50 milligram film coated tablet

rowex ltd - voriconazole - film coated tablet - 50 milligram - triazole derivatives

Voriconazole Actavis 50mg Film coated Tablets Malta - English - Medicines Authority

voriconazole actavis 50mg film coated tablets

actavis group ptc ehf - voriconazole - film-coated tablet - voriconazole 50 mg - antimycotics for systemic use

Voriconazole Actavis 200mg Film coated Tablets Malta - English - Medicines Authority

voriconazole actavis 200mg film coated tablets

actavis group ptc ehf - voriconazole - film-coated tablet - voriconazole 200 mg - antimycotics for systemic use

VORICONAZOLE ACTAVIS 200 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole actavis 200 milligram film coated tablet

actavis group ptc ehf - voriconazole - film coated tablet - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - it is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis. - treatment of candidemia in non-neutropenic patients. - treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). - treatment of serious fungal infections caused by scedosporium spp. and fusarium spp

VORICONAZOLE ACTAVIS 50 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole actavis 50 milligram film coated tablet

actavis group ptc ehf - voriconazole - film coated tablet - 50 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - it is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis. - treatment of candidemia in non-neutropenic patients. - treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). - treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.